About
About
I spent eight years at FDA. I led GMP inspections of small molecules, biologics and combination products, at home and abroad. I now work on the other side of that table, which mostly means asking what an investigator would actually see rather than what a procedure says should be visible.
Quality & Regulatory Consultant
I trained as a chemist. My first work in this industry was analytical: method development, and the slow, specific discipline of knowing what a number means before you act on it. That habit never left, and it turns out to be most of the job.
At FDA I was a lead investigator, running complex GMP inspections across small molecules, biologics and combination products, domestically and overseas. I also spent time evaluating process analytical technology back when investigators covered multiple product areas and had to go deep across all of them. That is why I took chemometrics courses in 2015, because you cannot evaluate what you do not understand.
Since leaving the agency I have worked as a consultant: building quality systems, running mock inspections, preparing sponsors for licence applications, and auditing the contract sites that do the actual manufacturing. I now run my own practice, Respress Solutions, working directly with clients and as an affiliate consultant to specialist GMP consultancies on larger programmes. Most recently that has meant licence-application and pre-license inspection readiness for advanced-therapy products.
What I am actually useful for is the uncomfortable read. I can tell you what an investigator would find, in what order, and how bad it would look, and then help you fix it in the time you have. I would rather give you a hard answer early than a reassuring one that does not survive the first day of an inspection.
Experience
Where I have worked
- May 2026–Present
Principal Consultant
Respress Solutions LLC · Longwood, FL · Remote
Independent quality and regulatory practice. I work directly with sponsors and manufacturers, and on contract as an affiliate consultant to Pioneer GMP Consulting on larger programmes.
- Regulatory and subject-matter lead on licence-application and pre-license inspection readiness for a cell and gene therapy sponsor, covering drug substance, drug product and commercial quality-system readiness.
- Built CMC deficiency registers and regulatory standards maps tracing every finding to the applicable CFR, ICH and EU GMP requirement.
- Directed contract-manufacturer audits and site-to-scope responsibility mapping across a multi-site manufacturing network.
- Published practical frameworks on inspection readiness under the Quality Management System Regulation.
- Dec 2024–Mar 2026
Principal Consultant
Pioneer GMP Consulting · Remote
Regulatory and GMP subject-matter lead on CMC-heavy engagements for drug and biologics manufacturers. The relationship continues on a contract basis.
- Led Annex 1 remediation across sterile manufacturing operations.
- Designed and delivered mock pre-approval and pre-license inspection programmes, including SME preparation and storyboarding.
- Spoke at ISPE on inspection readiness.
- Oct 2022–Jul 2023
Principal QA Director / Senior Quality Consultant
Azzur Group · Remote
Led quality-system implementation for multiple biotech clients while managing teams of five to ten consultants.
- Directed mock FDA and EMA audits for pharmaceutical and medical device companies.
- Established quality systems compliant with QSIT, ISO 13485, MDSAP and GMP requirements.
- Developed strategic remediation plans for critical quality-system gaps, including Annex 1 assessments for sterile manufacturing.
- May 2022–Oct 2022
Senior Health Scientist
U.S. Food and Drug Administration · Remote
Developed strategic quality and compliance plans supporting Office of Regulatory Affairs priorities.
- Led cross-functional teams on regulatory project implementation.
- Provided strategic input on FDA guidance documents and managed regulatory communications with industry stakeholders.
- Nov 2017–May 2022
Consumer Safety Officer (Lead Investigator)
U.S. Food and Drug Administration · Multiple locations
Led complex GMP inspections across small molecules, biologics and combination products, domestically and abroad.
- Conducted foreign and domestic inspections assessing compliance with FDA and EU requirements.
- Developed and implemented remote regulatory assessment programmes during COVID-19.
- Investigated critical quality issues and compliance concerns, including enforcement follow-up.
- Dec 2014–Nov 2017
Chemist (GMP Inspector & Analyst)
U.S. Food and Drug Administration · Jamaica, NY
GMP inspection and analytical work across multiple product areas, before the agency moved to commodity-specific investigator assignments.
- Evaluated process analytical technology, including near-infrared spectroscopy and multivariate calibration for real-time release.
- Apr 2010–Dec 2014
Scientist (Analytical Chemistry)
Forest Research Institute · Forest Laboratories · Commack, NY · Dublin, Ireland
Analytical chemistry and quality work, including a period as Quality Specialist in Dublin.
- Led corporate-wide quality-system harmonisation during the Forest Laboratories–Actavis merger, integrating more than 500 SOPs.
Capabilities
What I bring
Regulatory & inspections
- PAI, PLI, for-cause & surveillance inspections
- 21 CFR 210, 211, 600, 820, 58
- EU GMP & Annex 1
- ISO 13485 · QSIT · MDSAP
- Warning-letter & 483 response
Quality systems
- Investigations, CAPA & change control
- Risk-based supplier qualification
- Data integrity programmes
- QMS harmonisation across markets
- Inspection readiness programmes
Technical & platforms
- Biologics, small molecule & combination products
- Sterile and advanced-therapy manufacturing
- Process analytical technology & chemometrics
- MasterControl · Trackwise · Veeva QMS
- eCTD · LORENZ docuBridge
Education
- MSc Chemistry · Long Island University
- BSc Chemistry · York College, City University of New York
Certifications & training
- FDA Investigator Certification (Level I & II)
- EU GMP and Annex 1 Compliance
- QSIT & MDSAP Lead Auditor
- Risk-Based Compliance & Data Integrity
Is your site ready for the inspection you are not expecting?
Most of the findings I see were visible months earlier to anyone looking the way an investigator looks. A short conversation is usually enough to tell whether I can help.